Eli Lilly and Company (LLY) vs Merck & Co., Inc. (MRK)
Eli Lilly and Company and Merck & Co., Inc. are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.11T against $365.4B — 3.0× the size. Eli Lilly and Company trades at the lower P/E: 39.7× against 119×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 4.64%. Eli Lilly and Company has the higher net margin (33.5% vs 4.77%) and the higher return on invested capital (26.3% vs 5.08%). Both pay a dividend; Merck & Co., Inc. yields more (2.58% vs 0.72%). Across the 23 metrics below, Eli Lilly and Company leads on 13 and Merck & Co., Inc. on 10.
Valuation
Profitability
| Metric | LLY | MRK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 83.40% | 72.97% | 72.77% |
| Operating margin | 42.22% | 10.49% | 18.90% |
| Net margin | 33.53% | 4.77% | 8.27% |
| Free cash flow margin | 22.83% | 24.13% | 17.25% |
| Return on equity | 102.29% | 6.97% | 6.97% |
| Return on assets | 21.97% | 2.57% | 2.76% |
| Return on invested capital | 26.33% | 5.08% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack